Associate Professor Andrew Vizard (BVSc (Hons), MVPM)
Chairman & Independent Director

With a background in research and agricultural consultancy, Professor Vizard is the Senior Consultant with, and former Director of the Mackinnon Project at the University of Melbourne. This enterprise is recognised as a world leader in delivering practical advice to farmer and agribusiness on a wide range of agricultural and economic issues.  He is the author of over 50 scientific papers.

Professor Vizard has formerly been a board member of numerous statutory, scientifica and commercial organisations.  Currently a Non-Executive Director of Ridley Corporation Ltd and Animal Health Australia Ltd, a Trustee of the Australian Wool Education Trust and a member of the Management Advisory Committee for Melbourne Water. 

Professor Vizard is a member of the Company's Audit, Compliance and Corporate Governance Committee.

Harry Rosen (BA, LLB)
President & Chief Executive Officer

Mr Rosen is one of the founders of Betatene Limited and Denehurst Ltd, two formerly ASX-listed companies which commercialised significant research and development.  Betatene is the world's largest producer of natural beta carotene.  After the purchase of Betatene Limited by Henkel Corporation, Mr Rosen served as Vice President, Corporate Development.  As a Vice President of Henkel Corporation, he worked for a number of years in the US in the nutrition and health care industries.

Mr Rosen has consulted to many technology companies assisting them with the commercialisation of new technologies.  He has had significant experience in the areas of seed capital raising, stock exchange listings, taxation and corporate law.  Mr Rosen graduated from the Australian National University (BA-Psychology) and Melbourne University (LLB).

Dr Esra Ogru (BSc(Hons), PhD)
Chief Operating Officer

Dr Ogru is responsible for the management of the operations in Australia and internationally.  She achieves this through leadership of a team of experienced pharmaceutical scientists and chemists and strategic collaborations.

In this role, Dr Ogru has developed commercial opportunities for both the Company’s nutraceutical division and pharmaceutical technologies, such as transdermal drug delivery and drug enhancement platforms for cancer, heart disease and chronic pain management.

Dr Ogru has many years experience in both the academic and commercial aspects of the industry and has publications in peer-reviewed journals. Prior to joining Phosphagenics in 2001, Dr Ogru carried out significant research on obesity and diabetes.  Additionally, she has considerable experience in the management and coordination of pre-clinical and clinical development of pharmaceutical products.

Professor John Mills (BS (Hons), MD, FACP, FRACP)
Independent Director

Professor Mills has a long and distinguished career in medical research, clinical medicine and biomedical business.  In addition to his position as a Non-Executive Director of Phosphagenics, he is the Executive Chairman of Cavidi AB, an Executive Director of TissuePath Pty Ltd, a Non-Executive Director of GBS Venture Partners Pty Ltd.  He was previously a Non-Executive Director (1995-2003) and Chairman (2001-2002) of AMRAD Corporation, a Non-Executive Director of Narhex Life Sciences Ltd (2001-2005) and Managing Director from 2005 to December 2007. He is also a Non-Executive Director of the Prostate Cancer Foundation of Australia and Chair of the PCFA Research Committee.  He holds professorial appointments at Monash University, the University of California, San Francisco and RMIT, and is a consulting physician at The Alfred and Austin Hospitals in Melbourne.

He has published over 200 scientific articles and has served as a consultant to the pharmaceutical ndustry and governments, the World Health Organisation and the United Nations.

Professor Mills is a member of the Company’s Audit, Compliance and Corporate Governance Committee.

Jonathan Addison (BEc (Tas), ASIC, CFTP (Snr))
Independent Director

Mr Addison has over 30 years in the investment management industry, including wide experience in superannuation.  Currently he is the Investment Manager (formerly Fund Manager) of the Meat Industry Employee Superannuation Fund (MIESF) whom he joined in June 1999 and where he is responsible for the investment management of MIESF.

MIESF, a self-administered industry superannuation fund established in 1981 which operates nationally, currently holds 21,800,000 shares in Phosphagenics Limited.  Prior to his appointment to MIESF, Mr Addison was a Director and Asset Consultant within the corporate finance section of PricewaterhouseCoopers and in this role was responsible for establishing an investment consulting practice with clients ranging from superannuation funds to insurance funds and funds managers.  Prior to that, he was Manager Investment Consultant at Sedgwick Noble Lowndes.

Mr Addison also holds Non-Executive Directorships with Austcorp Group Limited, Austcorp Funds Management Limited, African Enterprise Limited, African Enterprises New Zealand Limited, Hawksbridge Limited, Global Masters Fund Limited and TPCG Limited.

Mr Addisson is the Chairman of the Company’s Audit, Compliance and Corporate Governance Committee.

Michael Ashton (BPharm, MBA)
Independent Director

Mr Ashton has more than 30 years’ experience in the international pharmaceutical industry having held senior management positions with Merck Inc. and Pfizer Inc., and executive board positions with Faulding Inc. and SkyePharma Plc. 

Mr Ashton was CEO and Director of SkyePharma Plc.  He was responsible for the re-organisation of SkyePharma AG as a public enterprise (1997-1998).  In 1998 he took over responsibility of the operations of SkyePharma Plc. group and re-organised the international structure in Europe, the US and the world wide Business Development Group. 

Earlier Mr Ashton was Chairman, President and CEO of Faulding Inc., the US subsidiary he opened for FH Faulding, Australia's largest pharmaceutical company, and CEO of Purepac Inc.  During that time, he supervised the start-up of David Bull in the US and Canada and oversaw restructuring of Purepac Inc. into a leader of the US generic pharmaceutical industry.

In addition, Mr Ashton served with Pfizer International for 14 years in various roles, which included Director of Pharmaceutical Business Development for Europe/Canada, Vice President of Pharmaceutical Development for Africa/Middle East, Pharmaceutical Business Director of Nigeria and Group Product Manager for the International Division in New York.

Mr Ashton previously applied his pharmacist background to various management positions during six years at Merck Sharp and Dohme in Sydney and the U.S.  He is a member of the Boards of Hikma Pharmaceuticals Plc., Proximagen Neuroscience Plc. and Transition Therapeutics Inc.

Mr Ashton holds a Bachelor of Pharmacy degree from Sydney University and a Masters in Business Administration from Rutger University, New Jersey, USA.